A GLP-1 medication currently under investigation as an injection and tablet in phase 3 clinical trials
L., Lambrechts, L., Cauchemez, S., Linard, C., Faria, N
Semaglutide works via subcutaneous injection, so any placement in the fatty tissue layer under your skin (within approved areas like the abdomen, thigh, or upper arm) will deliver the medication effectively
However, if severe vomiting or diarrhea occurs, patients should stop the medication immediately, as these symptoms could lead to acute kidney injury
The twins in WSJ s reporting began gaining weight around age 4, and despite all of their parents efforts to help them control their weight, continued to gain